An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels

American Journal of Translational Research

Volumn 8, Issue 2, 2016, Pages 246-269

  Zhou, Xiaoling ^a   Li, Yifei ^a   Shi, Xiaozhe ^a   Ma, Chun ^a  

^a CHANGCHUN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Antioxidants; Donepezil; Memantine; Screening; Statins

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE RECEPTOR; ALPHA METHYLHISTAMINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BUSPIRONE; CALPAIN; CAREBASTINE; CHLORPHENIRAMINE; CURCUMIN; DIMEBON; DONEPEZIL; ETAZOLATE; GABAPENTIN; GALANTAMINE; HISTAMINE; IDALOPIRDINE; LECOZOTAN; MEMANTINE; MEPYRAMINE; ONDANSETRON; PRESENILIN 1; RESVERATROL; RIVASTIGMINE; SIMVASTATIN; TACRINE; TANDOSPIRONE; THIOPERAMIDE; ZINC ION;

ALZHEIMER DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; GLUTAMATERGIC SYNAPSE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NEUROTRANSMISSION; OXIDATIVE STRESS; PLEIOTROPY; REVIEW; SEROTONINERGIC SYSTEM;

EID: 84962088954     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (239)

1. Coria F, Rubio I and Bayon C. Alzheimer’s disease, beta-amyloidosis, and aging. Rev Neurosci 1994; 5: 275-292.
2. Mattila J, Soininen H, Koikkalainen J, Rueckert D, Wolz R, Waldemar G and Lotjonen J. Optimizing the diagnosis of early Alzheimer’s disease in mild cognitive impairment subjects. J Alzheimers Dis 2012; 32: 969-979.
3. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
4. Haan MN and Wallace R. Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004; 25: 1-24.
5. Dufouil C and Alperovitch A. [Epidemiology of Alzheimer’s disease]. Rev Prat 2005; 55: 1869-1878.
6. Selkoe DJ and Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 2002; 3: 67-99.
7. Chin-Chan M, Navarro-Yepes J and Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci 2015; 9: 124.
8. Castellani RJ and Perry G. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol 2014; 88: 671-676.
9. Jia Q, Deng Y and Qing H. Potential therapeutic strategies for Alzheimer's disease targeting or beyond beta-amyloid: insights from clinical trials. Biomed Res Int 2014; 2014: 837157.
10. Arbogast CE, Welleford EA and Netting FE. State Dementia Plans and the Alzheimer’s Disease Movement: Framing Diagnosis, Prognosis, and Motivation. J Appl Gerontol 2015; [Epub ahead of print].
11. Iadecola C. Cerebrovascular effects of amyloidbeta peptides: mechanisms and implications for Alzheimer's dementia. Cell Mol Neurobiol 2003; 23: 681-689.
12. Thal DR, Griffin WS and Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer’s disease. J Cell Mol Med 2008; 12: 1848-1862.
13. Calkins MJ and Reddy PH. Amyloid beta impairs mitochondrial anterograde transport and degenerates synapses in Alzheimer’s disease neurons. Biochim Biophys Acta 2011; 1812: 507-513.
14. Canobbio I, Catricala S, Balduini C and Torti M. Calmodulin regulates the non-amyloidogenic metabolism of amyloid precursor protein in platelets. Biochim Biophys Acta 2011; 1813: 500-506.
15. O’Brien RJ and Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci 2011; 34: 185-204.
16. Zhang YW, Thompson R, Zhang H and Xu H. APP processing in Alzheimer’s disease. Mol Brain 2011; 4: 3.
17. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
18. Serrano-Pozo A, Frosch MP, Masliah E and Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
19. Paulson JB, Ramsden M, Forster C, Sherman MA, McGowan E and Ashe KH. Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer’s disease. Am J Pathol 2008; 173: 762-772.
20. Ferreira A and Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med 2011; 17: 676-685.
21. Orsucci D, Mancuso M, Ienco EC, Simoncini C, Siciliano G and Bonuccelli U. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer’s disease. Curr Neurovasc Res 2013; 10: 76-80.
22. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006; 66: S79-85.
23. Erickson MA and Banks WA. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab 2013; 33: 1500-1513.
24. Zou Z, Liu C, Che C and Huang H. Clinical genetics of Alzheimer’s disease. Biomed Res Int 2014; 2014: 291862.
25. Zadori D, Veres G, Szalardy L, Klivenyi P, Toldi J and Vecsei L. Glutamatergic dysfunctioning in Alzheimer’s disease and related therapeutic targets. J Alzheimers Dis 2014; 42 Suppl 3: S177-187.
26. Verhoeff NP. Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer’s disease. Expert Rev Neurother 2005; 5: 277-284.
27. Luchetti S, Huitinga I and Swaab DF. Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson’s disease and multiple sclerosis. Neuroscience 2011; 191: 6-21.
28. Zlomuzica A, Dere D, Binder S, De Souza Silva MA, Huston JP and Dere E. Neuronal histamine and cognitive symptoms in Alzheimer’s disease. Neuropharmacology 2015; [Epub ahead of print].
29. Rodriguez JJ, Noristani HN and Verkhratsky A. The serotonergic system in ageing and Alzheimer’s disease. Prog Neurobiol 2012; 99: 15-41.
30. Vasto S, Candore G, Listi F, Balistreri CR, Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D and Caruso C. Inflammation, genes and zinc in Alzheimer’s disease. Brain Res Rev 2008; 58: 96-105.
31. Bush AI. The metallobiology of Alzheimer’s disease. Trends Neurosci 2003; 26: 207-214.
32. Daneschvar HL, Aronson MD and Smetana GW. Do statins prevent Alzheimer’s disease? A narrative review. Eur J Intern Med 2015; 26: 666-9.
33. Francis PT, Palmer AM, Snape M and Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.
34. Thomsen T, Zendeh B, Fischer JP and Kewitz H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41: 139-141.
35. Anand P and Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res 2013; 36: 375-399.
36. Nagabukuro H, Hashimoto T, Iwata M and Doi T. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and tamsulosin, an alpha1- adrenoceptor antagonist, and their synergistic effects on the urodynamic characteristics in a guinea-pig model of functional bladder outlet obstruction. BJU Int 2005; 95: 1071-1076.
37. Park SM, Ki SH, Han NR, Cho IJ, Ku SK, Kim SC, Zhao RJ and Kim YW. Tacrine, an oral acetylcholinesterase inhibitor, induced hepatic oxidative damage, which was blocked by liquiritigenin through GSK3-beta inhibition. Biol Pharm Bull 2015; 38: 184-192.
38. Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C and Tumiatti V. Multifunctional tacrine derivatives in Alzheimer’s disease. Curr Top Med Chem 2013; 13: 1771-1786.
39. Li C, Carlier PR, Ren H, Kan KK, Hui K, Wang H, Li W, Li Z, Xiong K, Clement EC, Xue H, Liu X, Li M, Pang Y and Han Y. Alkylene tether-length dependent gamma-aminobutyric acid type A receptor competitive antagonism by tacrine dimers. Neuropharmacology 2007; 52: 436-443.
40. Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM and Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 2013; 11: 315-335.
41. Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A and Marco-Contelles J. Novel tacrine- related drugs as potential candidates for the treatment of Alzheimer’s disease. Bioorg Med Chem Lett 2013; 23: 1916-1922.
42. Alonso D, Dorronsoro I, Rubio L, Munoz P, Garcia-Palomero E, Del Monte M, Bidon- Chanal A, Orozco M, Luque FJ, Castro A, Medina M and Martinez A. Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. Bioorg Med Chem 2005; 13: 6588-6597.
43. Guzior N, Wieckowska A, Panek D and Malawska B. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer’s disease. Curr Med Chem 2015; 22: 373-404.
44. Lupp A, Appenroth D, Fang L, Decker M, Lehmann J and Fleck C. Tacrine-NO donor and tacrine- ferulic acid hybrid molecules as new anti- Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine. Arzneimittelforschung 2010; 60: 229-237.
45. Marco-Contelles J, Leon R, de Los Rios C, Guglietta A, Terencio J, Lopez MG, Garcia AG and Villarroya M. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer’s disease. J Med Chem 2006; 49: 7607-7610.
46. Huang L, Su T, Shan W, Luo Z, Sun Y, He F and Li X. Inhibition of cholinesterase activity and amyloid aggregation by berberine-phenyl-benzoheterocyclic and tacrine-phenyl-benzoheterocyclic hybrids. Bioorg Med Chem 2012; 20: 3038-3048.
47. Cacabelos R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat 2007; 3: 303-333.
48. Sugimoto H, Iimura Y, Yamanishi Y and Yamatsu K. Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl- 4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl] piperidine hydrochloride and related compounds. J Med Chem 1995; 38: 4821-4829.
49. Pang YP and Kozikowski AP. Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon- 2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program. J Comput Aided Mol Des 1994; 8: 683-693.
50. Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA and Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 2012; 37: 2310-2321.
51. Albuquerque EX, Santos MD, Alkondon M, Pereira EF and Maelicke A. Modulation of nicotinic receptor activity in the central nervous system: a novel approach to the treatment of Alzheimer disease. Alzheimer Dis Assoc Disord 2001; 15 Suppl 1: S19-25.
52. Greenblatt HM, Kryger G, Lewis T, Silman I and Sussman JL. Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett 1999; 463: 321-326.
53. Bolognesi ML, Bartolini M, Cavalli A, Andrisano V, Rosini M, Minarini A and Melchiorre C. Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. J Med Chem 2004; 47: 5945-5952.
54. Rodrigues Simoes MC, Dias Viegas FP, Moreira MS, de Freitas Silva M, Riquiel MM, da Rosa PM, Castelli MR, dos Santos MH, Soares MG and Viegas C Jr. Donepezil: an important prototype to the design of new drug candidates for Alzheimer’s disease. Mini Rev Med Chem 2014; 14: 2-19.
55. Toda N, Tago K, Marumoto S, Takami K, Ori M, Yamada N, Koyama K, Naruto S, Abe K, Yamazaki R, Hara T, Aoyagi A, Abe Y, Kaneko T and Kogen H. Design, synthesis and structureactivity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer’s disease. Bioorg Med Chem 2003; 11: 1935-1955.
56. Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M, Andrisano V, Cavalli A, Recanatini M and Valenti P. Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase- induced beta-amyloid aggregation. J Med Chem 2005; 48: 4444-4456.
57. Anand P and Singh B. Synthesis and evaluation of novel 4-[(3H,3aH,6aH)-3-phenyl)-4,6- dioxo-2-phenyldihydro-2H-pyrrolo[(3,4-d]isoxazol- 5(3H,6H,6aH)-yl]benzoic acid derivatives as potent acetylcholinesterase inhibitors and anti-amnestic agents. Bioorg Med Chem 2012; 20: 521-530.
58. Razavi SF, Khoobi M, Nadri H, Sakhteman A, Moradi A, Emami S, Foroumadi A and Shafiee A. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors. Eur J Med Chem 2013; 64: 252-259.
59. Rizzo S, Bartolini M, Ceccarini L, Piazzi L, Gobbi S, Cavalli A, Recanatini M, Andrisano V and Rampa A. Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem 2010; 18: 1749-1760.
60. Shen Y, Zhang J, Sheng R, Dong X, He Q, Yang B and Hu Y. Synthesis and biological evaluation of novel flavonoid derivatives as dual binding acetylcholinesterase inhibitors. J Enzyme Inhib Med Chem 2009; 24: 372-380.
61. Sawasdee P, Sabphon C, Sitthiwongwanit D and Kokpol U. Anticholinesterase activity of 7-methoxyflavones isolated from Kaempferia parviflora. Phytother Res 2009; 23: 1792-1794.
62. Walton HS and Dodd PR. Glutamate-glutamine cycling in Alzheimer’s disease. Neurochem Int 2007; 50: 1052-1066.
63. Innocent N, Cousins SL and Stephenson FA. NMDA receptor/amyloid precursor protein interactions: a comparison between wild-type and amyloid precursor protein mutations associated with familial Alzheimer’s disease. Neurosci Lett 2012; 515: 131-136.
64. Golde TE. Disease modifying therapy for AD? J Neurochem 2006; 99: 689-707.
65. Farlow MR, Graham SM and Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf 2008; 31: 577-585.
66. Cummings JL. Treatment of Alzheimer’s disease: the role of symptomatic agents in an era of disease-modifying therapies. Rev Neurol Dis 2007; 4: 57-62.
67. Gilling KE, Jatzke C, Hechenberger M and Parsons CG. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/ GluN2A) receptors. Neuropharmacology 2009; 56: 866-875.
68. Danysz W and Parsons CG. Alzheimer’s disease, beta-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol 2012; 167: 324-352.
69. Miguel-Hidalgo JJ, Paul IA, Wanzo V and Banerjee PK. Memantine prevents cognitive impairment and reduces Bcl-2 and caspase 8 immunoreactivity in rats injected with amyloid beta1-40. Eur J Pharmacol 2012; 692: 38-45.
70. Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci 2012; 13: 2219-2238.
71. Dominguez E, Chin TY, Chen CP and Wu TY. Management of moderate to severe Alzheimer’s disease: focus on memantine. Taiwan J Obstet Gynecol 2011; 50: 415-423.
72. Prokselj T, Jerin A and Kogoj A. Memantine may affect pseudobulbar affect in patients with Alzheimer’s disease. Acta Neuropsychiatr 2013; 25: 361-366.
73. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I and Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013; 5: 6.
74. Gauthier S and Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement 2013; 9: 326-331.
75. Bell KF, de Kort GJ, Steggerda S, Shigemoto R, Ribeiro-da-Silva A and Cuello AC. Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology. Neurosci Lett 2003; 353: 143-147.
76. Ulrich D. Amyloid-beta Impairs Synaptic Inhibition via GABA(A) Receptor Endocytosis. J Neurosci 2015; 35: 9205-9210.
77. Jansen KL, Faull RL, Dragunow M and Synek BL. Alzheimer's disease: changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors--an autoradiographic study. Neuroscience 1990; 39: 613-627.
78. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F and Desire L. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008; 106: 392-404.
79. Cooney C, Murphy S, Tessema H and Freyne A. Use of low-dose gabapentin for aggressive behavior in vascular and Mixed Vascular/ Alzheimer Dementia. J Neuropsychiatry Clin Neurosci 2013; 25: 120-125.
80. Adam F, Bordenave L, Sessler DI and Chauvin M. Effects of a single 1200-mg preoperative dose of gabapentin on anxiety and memory. Ann Fr Anesth Reanim 2012; 31: e223-227.
81. Lin TW and Kuo YM. Exercise benefits brain function: the monoamine connection. Brain Sci 2013; 3: 39-53.
82. Chen CP, Eastwood SL, Hope T, McDonald B, Francis PT and Esiri MM. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer’s disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol 2000; 26: 347-355.
83. Cochet M, Donneger R, Cassier E, Gaven F, Lichtenthaler SF, Marin P, Bockaert J, Dumuis A and Claeysen S. 5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci 2013; 4: 130-140.
84. Hedlund PB and Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 2004; 25: 481-486.
85. Ramirez MJ. 5-HT6 receptors and Alzheimer’s disease. Alzheimers Res Ther 2013; 5: 15.
86. Madjid N, Tottie EE, Luttgen M, Meister B, Sandin J, Kuzmin A, Stiedl O and Ogren SO. 5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms. J Pharmacol Exp Ther 2006; 316: 581-591.
87. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE and Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther 2005; 314: 1274-1289.
88. Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A and Meltzer HY. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double- blind, placebo-controlled study. Schizophr Res 2007; 95: 158-168.
89. Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ and Shemer A. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol 1992; 12: 341-345.
90. Ramirez MJ, Lai MK, Tordera RM and Francis PT. Serotonergic therapies for cognitive symptoms in Alzheimer’s disease: rationale and current status. Drugs 2014; 74: 729-736.
91. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, Gold M, Hopton G, Jacobs G, Davy M and Williams P. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB- 742457, in Alzheimer’s disease. Curr Alzheimer Res 2010; 7: 374-385.
92. Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J and Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011; 26: 536-544.
93. Bezprozvanny I. The rise and fall of Dimebon. Drug News Perspect 2010; 23: 518-523.
94. MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, Huntington PJ, Estill SJ, Longgood J, Becker GL, McKnight SL, Pieper AA, De Brabander JK and Ready JM. Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc 2011; 133: 1428-1437.
95. Kendall I, Slotten HA, Codony X, Burgueno J, Pauwels PJ, Vela JM and Fone KC. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 2011; 213: 413-430.
96. Nagy CF, Kumar D, Perdomo CA, Wason S, Cullen EI and Pratt RD. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol 2004; 58 Suppl 1: 25-33.
97. Keowkase R, Aboukhatwa M and Luo Y. Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans. Neuropharmacology 2010; 59: 358-365.
98. Kohler CA, da Silva WC, Benetti F and Bonini JS. Histaminergic mechanisms for modulation of memory systems. Neural Plast 2011; 2011: 328602.
99. Dai H, Kaneko K, Kato H, Fujii S, Jing Y, Xu A, Sakurai E, Kato M, Okamura N, Kuramasu A and Yanai K. Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. Neurosci Res 2007; 57: 306-313.
100. Threlfell S, Cragg SJ, Kallo I, Turi GF, Coen CW and Greenfield SA. Histamine H3 receptors inhibit serotonin release in substantia nigra pars reticulata. J Neurosci 2004; 24: 8704-8710.
101. Philippu A and Prast H. Importance of histamine in modulatory processes, locomotion and memory. Behav Brain Res 2001; 124: 151-159.
102. Naddafi F and Mirshafiey A. The neglected role of histamine in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2013; 28: 327-336.
103. Geng S, Gao YD, Yang J, Zou JJ and Guo W. Potential role of store-operated Ca2+ entry in Th2 response induced by histamine in human monocyte-derived dendritic cells. Int Immunopharmacol 2012; 12: 358-367.
104. Mizuguchi H, Ono S, Hattori M and Fukui H. Inverse agonistic activity of antihistamines and suppression of histamine H1 receptor gene expression. J Pharmacol Sci 2012; 118: 117-121.
105. Motawaj M, Peoc’h K, Callebert J and Arrang JM. CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer’s disease. J Alzheimers Dis 2010; 22: 861-871.
106. Kharmate G, Liu Z, Patterson E and Khan MM. Histamine affects STAT6 phosphorylation via its effects on IL-4 secretion: role of H1 receptors in the regulation of IL-4 production. Int Immunopharmacol 2007; 7: 277-286.
107. Baronio D, Gonchoroski T, Castro K, Zanatta G, Gottfried C and Riesgo R. Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry 2014; 13: 34.
108. Passani MB and Blandina P. Cognitive implications for H3 and 5-HT3 receptor modulation of cortical cholinergic function: a parallel story. Methods Find Exp Clin Pharmacol 1998; 20: 725-733.
109. Bermejo P, Martin-Aragon S, Benedi J, Susin C, Felici E, Gil P, Ribera JM and Villar AM. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer’s disease. Immunol Lett 2008; 117: 198-202.
110. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V and Baloyannis S. Systemic immune aberrations in Alzheimer’s disease patients. J Neuroimmunol 2008; 193: 183-187.
111. Rivera-Oliver M and Diaz-Rios M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 2014; 101: 1-9.
112. Gahr M, Nowak DA, Connemann BJ and Schonfeldt-Lecuona C. Cerebral Amyloidal Angiopathy--a disease with implications for neurology and psychiatry. Brain Res 2013; 1519: 19-30.
113. Cupino TL and Zabel MK. Alzheimer’s silent partner: cerebral amyloid angiopathy. Transl Stroke Res 2014; 5: 330-337.
114. Zeitlin R, Patel S, Burgess S, Arendash GW and Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer’s transgenic mice. Brain Res 2011; 1417: 127-136.
115. Gelber RP, Petrovitch H, Masaki KH, Ross GW and White LR. Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis 2011; 23: 607-615.
116. Melani A, Pantoni L, Bordoni F, Gianfriddo M, Bianchi L, Vannucchi MG, Bertorelli R, Monopoli A and Pedata F. The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. Brain Res 2003; 959: 243-250.
117. Azizi G, Navabi SS, Al-Shukaili A, Seyedzadeh MH, Yazdani R and Mirshafiey A. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’s Disease. Sultan Qaboos Univ Med J 2015; 15: e305-316.
118. Rubio-Perez JM and Morillas-Ruiz JM. A review: inflammatory process in Alzheimer’s disease, role of cytokines. ScientificWorldJournal 2012; 2012: 756357.
119. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J and Campos-Pena V. Inflammatory process in Alzheimer’s Disease. Front Integr Neurosci 2013; 7: 59.
120. Ribizzi G, Fiordoro S, Barocci S, Ferrari E and Megna M. Cytokine polymorphisms and Alzhei mer disease: possible associations. Neurol Sci 2010; 31: 321-325.
121. Lee SJ, Drabik K, Van Wagoner NJ, Lee S, Choi C, Dong Y and Benveniste EN. ICAM-1-induced expression of proinflammatory cytokines in astrocytes: involvement of extracellular signalregulated kinase and p38 mitogen-activated protein kinase pathways. J Immunol 2000; 165: 4658-4666.
122. Greer MM. Inflammation and the pathophysiology of Alzheimer’s disease. Dialogues Clin Neurosci 2000; 2: 233-239.
123. Yeh ET. A new perspective on the biology of C-reactive protein. Circ Res 2005; 97: 609-611.
124. Guo JT, Yu J, Grass D, de Beer FC and Kindy MS. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 2002; 22: 5900-5909.
125. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata- Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G and Wyss-Coray T. Inflammation and Alzheimer’s disease. Neurobiol Aging 2000; 21: 383-421.
126. Richardson C, Gard PR, Klugman A, Isaac M and Tabet N. Blood pro-inflammatory cytokines in Alzheimer’s disease in relation to the use of acetylcholinesterase inhibitors. Int J Geriatr Psychiatry 2013; 28: 1312-1317.
127. Colton CA, Chernyshev ON, Gilbert DL and Vitek MP. Microglial contribution to oxidative stress in Alzheimer’s disease. Ann N Y Acad Sci 2000; 899: 292-307.
128. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J and Roher AE. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer’s disease. J Biol Chem 1998; 273: 29719-29726.
129. Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS and Koistinaho J. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A 2002; 99: 1610-1615.
130. Shen Y, Yang L and Li R. What does complement do in Alzheimer’s disease? Old molecules with new insights. Transl Neurodegener 2013; 2: 21.
131. Lue LF and Walker DG. Modeling Alzheimer’s disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci Res 2002; 70: 599-610.
132. Szekely CA and Zandi PP. Non-steroidal antiinflammatory drugs and Alzheimer’s disease: the epidemiological evidence. CNS Neurol Disord Drug Targets 2010; 9: 132-139.
133. Hoozemans JJ, Veerhuis R, Janssen I, Rozemuller AJ and Eikelenboom P. Interleukin- 1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer’s disease. Exp Gerontol 2001; 36: 559-570.
134. Blom MA, van Twillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R and Eikelenboom P. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Res 1997; 777: 210-218.
135. Choi SH, Aid S, Caracciolo L, Minami SS, Niikura T, Matsuoka Y, Turner RS, Mattson MP and Bosetti F. Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease. J Neurochem 2013; 124: 59-68.
136. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH and Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-449.
137. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D, Morgan D and Gordon MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin- 1 transgenic mice. J Neurosci 2002; 22: 2246-2254.
138. Cole GM, Morihara T, Lim GP, Yang F, Begum A and Frautschy SA. NSAID and antioxidant prevention of Alzheimer’s disease: lessons from in vitro and animal models. Ann N Y Acad Sci 2004; 1035: 68-84.
139. Papadopoulos P, Rosa-Neto P, Rochford J and Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer’s disease with combined amyloid-beta and cerebrovascular pathology. PLoS One 2013; 8: e68612.
140. Nenov MN, Laezza F, Haidacher SJ, Zhao Y, Sadygov RG, Starkey JM, Spratt H, Luxon BA, Dineley KT and Denner L. Cognitive enhancing treatment with a PPARgamma agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice. J Neurosci 2014; 34: 1028-1036.
141. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu- Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F and Heneka MT. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006; 103: 443-448.
142. Kubo T, Yamaguchi A, Iwata N and Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008; 4: 605-615.
143. Rogers JT and Lahiri DK. Metal and inflammatory targets for Alzheimer’s disease. Curr Drug Targets 2004; 5: 535-551.
144. Bleumink GS, Feenstra J, Sturkenboom MC and Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003; 63: 525-534.
145. Whelton A and Hamilton CW. Nonsteroidal antiinflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588-598.
146. Satoh H and Takeuchi K. Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Curr Med Chem 2012; 19: 82-89.
147. Imbimbo BP, Solfrizzi V and Panza F. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment? Front Aging Neurosci 2010; 2.
148. Stoltenberg M, Bruhn M, Sondergaard C, Doering P, West MJ, Larsen A, Troncoso JC and Danscher G. Immersion autometallographic tracing of zinc ions in Alzheimer betaamyloid plaques. Histochem Cell Biol 2005; 123: 605-611.
149. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL and Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998; 158: 47-52.
150. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, Stoltenberg M and Ravid R. Increased amount of zinc in the hippocampus and amygdala of Alzheimer’s diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997; 76: 53-59.
151. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A and Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta- amyloid deposits in Alzheimer’s disease. J Struct Biol 2006; 155: 30-37.
152. Yumoto S, Kakimi S, Ohsaki A and Ishikawa A. Demonstration of aluminum in amyloid fibers in the cores of senile plaques in the brains of patients with Alzheimer’s disease. J Inorg Biochem 2009; 103: 1579-1584.
153. Yang X, Yang Y, Li G, Wang J and Yang ES. Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci 2008; 34: 165-171.
154. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS and Smith MA. Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 2003; 16: 77-81.
155. Velez-Pardo C, Ospina GG and Jimenez del Rio M. Abeta[25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase- 3, NF-kappaB, p53 and c-Jun. Neurotoxicology 2002; 23: 351-365.
156. Ghribi O, Golovko MY, Larsen B, Schrag M and Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol- enriched diets. J Neurochem 2006; 99: 438-449.
157. Lu PH, Lee GJ, Raven EP, Tingus K, Khoo T, Thompson PM and Bartzokis G. Age-related slowing in cognitive processing speed is associated with myelin integrity in a very healthy elderly sample. J Clin Exp Neuropsychol 2011; 33: 1059-1068.
158. Thomson AM, Rogers JT and Leedman PJ. Ironregulatory proteins, iron-responsive elements and ferritin mRNA translation. Int J Biochem Cell Biol 1999; 31: 1139-1152.
159. Pinero DJ, Hu J and Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer’s diseased brains. Cell Mol Biol (Noisy-le-grand) 2000; 46: 761-776.
160. Silvestri L and Camaschella C. A potential pathogenetic role of iron in Alzheimer’s disease. J Cell Mol Med 2008; 12: 1548-1550.
161. Atwood CS, Huang X, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE and Bush AI. Copper catalyzed oxidation of Alzheimer Abeta. Cell Mol Biol (Noisy-le-grand) 2000; 46: 777-783.
162. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE and Bush AI. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998; 273: 12817-12826.
163. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G and Nakamura M. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med 2007; 43: 1552-1559.
164. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G and Frederickson CJ. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res 2000; 852: 274-278.
165. Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K and Masters CL. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem 1993; 268: 16109-16112.
166. Kambe T, Yamaguchi-Iwai Y, Sasaki R and Nagao M. Overview of mammalian zinc transporters. Cell Mol Life Sci 2004; 61: 49-68.
167. Multhaup G, Mechler H and Masters CL. Characterization of the high affinity heparin binding site of the Alzheimer’s disease beta A4 amyloid precursor protein (APP) and its enhancement by zinc(II). J Mol Recognit 1995; 8: 247-257.
168. Cuajungco MP and Lees GJ. Zinc metabolism in the brain: relevance to human neurodegenerative disorders. Neurobiol Dis 1997; 4: 137-169.
169. Pratico D, Uryu K, Sung S, Tang S, Trojanowski JQ and Lee VM. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J 2002; 16: 1138-1140.
170. Polizzi S, Pira E, Ferrara M, Bugiani M, Papaleo A, Albera R and Palmi S. Neurotoxic effects of aluminium among foundry workers and Alzheimer’s disease. Neurotoxicology 2002; 23: 761-774.
171. Hegde ML, Anitha S, Latha KS, Mustak MS, Stein R, Ravid R and Rao KS. First evidence for helical transitions in supercoiled DNA by amyloid Beta Peptide (1-42) and aluminum: a new insight in understanding Alzheimer’s disease. J Mol Neurosci 2004; 22: 19-31.
172. Amit T, Avramovich-Tirosh Y, Youdim MB and Mandel S. Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 2008; 22: 1296-1305.
173. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L and Zatta P. Challenges associated with metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis 2009; 17: 457-468.
174. Mandel S, Amit T, Bar-Am O and Youdim MB. Iron dysregulation in Alzheimer’s disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 2007; 82: 348-360.
175. Mecocci P and Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 2012; 1822: 631-638.
176. Yatin SM, Varadarajan S and Butterfield DA. Vitamin E Prevents Alzheimer’s Amyloid beta- Peptide (1-42)-Induced Neuronal Protein Oxidation and Reactive Oxygen Species Production. J Alzheimers Dis 2000; 2: 123-131.
177. Sung S, Yao Y, Uryu K, Yang H, Lee VM, Trojanowski JQ and Pratico D. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J 2004; 18: 323-325.
178. Yao Y, Chinnici C, Tang H, Trojanowski JQ, Lee VM and Pratico D. Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. J Neuroinflammation 2004; 1: 21.
179. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS and Thal LJ. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216-1222.
180. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61: 82-88.
181. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN and Guarino PD. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014; 311: 33-44.
182. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer’s Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005; 352: 2379-2388.
183. Lee J, Boo JH and Ryu H. The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start? Adv Drug Deliv Rev 2009; 61: 1316-1323.
184. Gutzmann H and Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease: update on a 2-year double- blind multicentre study. J Neural Transm Suppl 1998; 54: 301-310.
185. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E and Thomas RG. Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 2003; 61: 1498-1502.
186. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA and Perry G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer’s disease. Free Radic Res 2009; 43: 156-164.
187. Pocernich CB, Lange ML, Sultana R and Butterfield DA. Nutritional approaches to modulate oxidative stress in Alzheimer’s disease. Curr Alzheimer Res 2011; 8: 452-469.
188. Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L and Kaye J. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 2014; 38: 111-120.
189. Ono K, Hirohata M and Yamada M. Alpha-lipoic acid exhibits anti-amyloidogenicity for betaamyloid fibrils in vitro. Biochem Biophys Res Commun 2006; 341: 1046-1052.
190. McManus MJ, Murphy MP and Franklin JL. The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci 2011; 31: 15703-15715.
191. Kapay NA, Isaev NK, Stelmashook EV, Popova OV, Zorov DB, Skrebitsky VG and Skulachev VP. In vivo injected mitochondria-targeted plastoquinone antioxidant SkQR1 prevents beta-amyloid- induced decay of long-term potentiation in rat hippocampal slices. Biochemistry (Mosc) 2011; 76: 1367-1370.
192. Calkins MJ, Manczak M, Mao P, Shirendeb U and Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet 2011; 20: 4515-4529.
193. Chernyak BV, Antonenko YN, Domnina LV, Ivanova OY, Lyamzaev KG, Pustovidko AV, Rokitskaya TI, Severina, II, Simonyan RA, Trendeleva TA and Zvyagilskaya RA. Novel penetrating cations for targeting mitochondria. Curr Pharm Des 2013; 19: 2795-2806.
194. Anand R, Gill KD and Mahdi AA. Therapeutics of Alzheimer’s disease: Past, present and future. Neuropharmacology 2014; 76 Pt A: 27-50.
195. Robinson RA, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, Pierce W, St Clair DK, Markesbery WR and Butterfield DA. Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer’s disease. Proteomics 2011; 11: 4243-4256.
196. Butterfield DA and Poon HF. The senescenceaccelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer’s disease. Exp Gerontol 2005; 40: 774-783.
197. Parachikova A, Green KN, Hendrix C and LaFerla FM. Formulation of a medical food cocktail for Alzheimer’s disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One 2010; 5: e14015.
198. Javed H, Khan MM, Ahmad A, Vaibhav K, Ahmad ME, Khan A, Ashafaq M, Islam F, Siddiqui MS, Safhi MM and Islam F. Rutin prevents cognitive impairments by ameliorating oxidative stress and neuroinflammation in rat model of sporadic dementia of Alzheimer type. Neuroscience 2012; 210: 340-352.
199. Vijayapadma V, Ramyaa P, Pavithra D and Krishnasamy R. Protective effect of lutein against benzo(a)pyrene-induced oxidative stress in human erythrocytes. Toxicol Ind Health 2014; 30: 284-293.
200. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA and Cole GM. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280: 5892-5901.
201. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL and Cole GM. Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 2012; 4: 43.
202. Joseph JA, Denisova NA, Arendash G, Gordon M, Diamond D, Shukitt-Hale B and Morgan D. Blueberry supplementation enhances signaling and prevents behavioral deficits in an Alzheimer disease model. Nutr Neurosci 2003; 6: 153-162.
203. Ho L, Chen LH, Wang J, Zhao W, Talcott ST, Ono K, Teplow D, Humala N, Cheng A, Percival SS, Ferruzzi M, Janle E, Dickstein DL and Pasinetti GM. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer’s disease-type neuropathology and cognitive deterioration. J Alzheimers Dis 2009; 16: 59-72.
204. Orgogozo JM, Dartigues JF, Lafont S, Letenneur L, Commenges D, Salamon R, Renaud S and Breteler MB. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris) 1997; 153: 185-192.
205. Zhou J, Zhang S, Zhao X and Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res 2008; 45: 157-165.
206. He P, Ouyang X, Zhou S, Yin W, Tang C, Laudon M and Tian S. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ disease. Horm Behav 2013; 64: 1-7.
207. Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, Ikejima T and Nabeshima T. Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 2009; 157: 1270-1277.
208. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J and Quinn JF. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol 2003; 184: 510-520.
209. Prasanthi JR, Dasari B, Marwarha G, Larson T, Chen X, Geiger JD and Ghribi O. Caffeine protects against oxidative stress and Alzheimer’s disease-like pathology in rabbit hippocampus induced by cholesterol-enriched diet. Free Radic Biol Med 2010; 49: 1212-1220.
210. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM and Potter H. Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer’s disease transgenic mice. J Alzheimers Dis 2009; 17: 681-697.
211. Kim TI, Lee YK, Park SG, Choi IS, Ban JO, Park HK, Nam SY, Yun YW, Han SB, Oh KW and Hong JT. l-Theanine, an amino acid in green tea, attenuates beta-amyloid-induced cognitive dysfunction and neurotoxicity: reduction in oxidative damage and inactivation of ERK/p38 kinase and NF-kappaB pathways. Free Radic Biol Med 2009; 47: 1601-1610.
212. Iuvone T, De Filippis D, Esposito G, D’Amico A and Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-beta peptide-induced neurotoxicity. J Pharmacol Exp Ther 2006; 317: 1143-1149.
213. Zhao BL, Li XJ, He RG, Cheng SJ and Xin WJ. Scavenging effect of extracts of green tea and natural antioxidants on active oxygen radicals. Cell Biophys 1989; 14: 175-185.
214. Goodman Y, Steiner MR, Steiner SM and Mattson MP. Nordihydroguaiaretic acid protects hippocampal neurons against amyloid beta-peptide toxicity, and attenuates free radical and calcium accumulation. Brain Res 1994; 654: 171-176.
215. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT and Jordan-Sciutto KL. Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 2007; 66: 75-85.
216. Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A and Beal MF. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet 2012; 21: 5091-5105.
217. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H, Yamamoto M, Yla-Herttuala S, Levonen AL and Koistinaho J. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci 2008; 39: 302-313.
218. Ehehalt R, Keller P, Haass C, Thiele C and Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 2003; 160: 113-123.
219. Wong BX, Hung YH, Bush AI and Duce JA. Metals and cholesterol: two sides of the same coin in Alzheimer’s disease pathology. Front Aging Neurosci 2014; 6: 91.
220. Pierrot N, Tyteca D, D’Auria L, Dewachter I, Gailly P, Hendrickx A, Tasiaux B, Haylani LE, Muls N, N’Kuli F, Laquerriere A, Demoulin JB, Campion D, Brion JP, Courtoy PJ, Kienlen- Campard P and Octave JN. Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med 2013; 5: 608-625.
221. Mukherjee P, Faber AC, Shelton LM, Baek RC, Chiles TC and Seyfried TN. Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. J Lipid Res 2008; 49: 929-938.
222. Hicks DA, Nalivaeva NN and Turner AJ. Lipid rafts and Alzheimer’s disease: protein-lipid interactions and perturbation of signaling. Front Physiol 2012; 3: 189.
223. Liu CC, Kanekiyo T, Xu H and Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013; 9: 106-118.
224. Zhang H, Wu LM and Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm 2011; 2011: 949072.
225. Takeda S, Sato N and Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci 2014; 6: 171.
226. Phan HT, Hata T, Morita M, Yoda T, Hamada T, Vestergaard MC and Takagi M. The effect of oxysterols on the interaction of Alzheimer’s amyloid beta with model membranes. Biochim Biophys Acta 2013; 1828: 2487-2495.
227. Vatassery GT, Smith WE, Quach HT and Lai JC. In vitro oxidation of vitamin E, vitamin C, thiols and cholesterol in rat brain mitochondria incubated with free radicals. Neurochem Int 1995; 26: 527-535.
228. Arciello M, Gori M and Balsano C. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress. Oxid Med Cell Longev 2013; 2013: 971024.
229. Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H and Morishita R. Possible modification of Alzheimer’s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci 2014; 6: 71.
230. Kou J, Song M, Pattanayak A, Lim JE, Yang J, Cao D, Li L and Fukuchi K. Combined treatment of Abeta immunization with statin in a mouse model of Alzheimer’s disease. J Neuroimmunol 2012; 244: 70-83.
231. Buxbaum JD, Cullen EI and Friedhoff LT. Pharmacological concentrations of the HMGCoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci 2002; 7: a50-59.
232. Friedhoff LT, Cullen EI, Geoghagen NS and Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol 2001; 4: 127-130.
233. Zhang LL, Sui HJ, Liang B, Wang HM, Qu WH, Yu SX and Jin Y. Atorvastatin prevents amyloidbeta peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacol Sin 2014; 35: 716-726.
234. Cordle A and Landreth G. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. J Neurosci 2005; 25: 299-307.
235. Vaughan CJ and Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999; 30: 1969-1973.
236. Butterfield DA, Barone E and Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 2011; 64: 180-186.
237. Barone E, Di Domenico F and Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 2014; 88: 605-616.
238. Mancuso C, Santangelo R and Calabrese V. The heme oxygenase/biliverdin reductase system: a potential drug target in Alzheimers disease. J Biol Regul Homeost Agents 2013; 27: 75-87.
239. Ehret MJ and Chamberlin KW. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Clin Ther 2015; 37: 1604-1616.